[1] |
中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南(2018版)[J]. 中华皮肤科杂志, 2019,52(1):1⁃5. doi: 10.3760/cma.j.issn.0412⁃4030.2019.01.001.
|
[2] |
Maurer M, Fluhr JW, Khan DA. How to approach chronic inducible urticaria[J]. J Allergy Clin Immunol Pract, 2018,6(4):1119⁃1130. doi: 10.1016/j.jaip.2018.03.007.
|
[3] |
Maurer M, Hawro T, Krause K, et al. Diagnosis and treatment of chronic inducible urticaria[J]. Allergy, 2019,74(12):2550⁃2553. doi: 10.1111/all.13878.
|
[4] |
Kocatürk E, Can PK, Akbas PE, et al. Management of chronic inducible urticaria according to the guidelines: a prospective controlled study[J]. J Dermatol Sci, 2017,87(1):60⁃69. doi: 10. 1016/j.jdermsci.2017.02.283.
|
[5] |
Pereira A, Motta AA, Kalil J, et al. Chronic inducible urticaria: confirmation through challenge tests and response to treatment[J]. Einstein (Sao Paulo), 2020,18:eAO5175. doi: 10.31744/einstein_journal/2020ao5175.
|
[6] |
Fukunaga A, Washio K, Hatakeyama M, et al. Cholinergic urticaria: epidemiology, physiopathology, new categorization, and management[J]. Clin Auton Res, 2018,28(1):103⁃113. doi: 10. 1007/s10286⁃017⁃0418⁃6.
|
[7] |
Maltseva N, Borzova E, Fomina D, et al. Cold urticaria ⁃ what we know and what we do not know[J]. Allergy, 2021,76(4):1077⁃1094. doi: 10.1111/all.14674.
|
[8] |
Pezzolo E, Peroni A, Gisondi P, et al. Heat urticaria: a revision of published cases with an update on classification and management[J]. Br J Dermatol, 2016,175(3):473⁃478. doi: 10.1111/bjd. 14543.
|
[9] |
Dressler C, Werner RN, Eisert L, et al. Chronic inducible urticaria: a systematic review of treatment options[J]. J Allergy Clin Immunol, 2018,141(5):1726⁃1734. doi: 10.1016/j.jaci.2018. 01.031.
|
[10] |
Cassano N, Mastrandrea V, Vestita M, et al. An overview of delayed pressure urticaria with special emphasis on pathogenesis and treatment[J]. Dermatol Ther, 2009,22 Suppl 1:S22⁃S26. doi: 10.1111/j.1529⁃8019.2009.01268.x.
|
[11] |
Morgado⁃Carrasco D, Fustà⁃Novell X, Podlipnik S, et al. Clinical and photobiological response in eight patients with solar urticaria under treatment with omalizumab, and review of the literature[J]. Photodermatol Photoimmunol Photomed, 2018,34(3):194⁃199. doi: 10.1111/phpp.12370.
|
[12] |
Kulthanan K, Ungprasert P, Tuchinda P, et al. Symptomatic dermographism: a systematic review of treatment options[J]. J Allergy Clin Immunol Pract, 2020,8(9):3141⁃3161. doi: 10. 1016/j.jaip.2020.05.016.
|
[13] |
Wang F, Zhao YK, Luo ZY, et al. Aquagenic cutaneous disorders[J]. J Dtsch Dermatol Ges, 2017,15(6):602⁃608. doi: 10.1111/ddg.13234.
|
[14] |
Magerl M, Altrichter S, Borzova E, et al. The definition, diagnostic testing, and management of chronic inducible urticarias ⁃ The EAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision[J]. Allergy, 2016,71(6):780⁃802. doi: 10.1111/all.12884.
|
[15] |
Kozaru T, Fukunaga A, Taguchi K, et al. Rapid desensitization with autologous sweat in cholinergic urticaria[J]. Allergol Int, 2011,60(3):277⁃281. doi: 10.2332/allergolint.10⁃OA⁃0269.
|
[16] |
Kring Tannert L, Stahl Skov P, Bjerremann Jensen L, et al. Cold urticaria patients exhibit normal skin levels of functional mast cells and histamine after tolerance induction[J]. Dermatology, 2012,224(2):101⁃105. doi: 10.1159/000336572.
|
[17] |
Pezzolo E, Peroni A, Gisondi P, et al. Heat urticaria: a revision of published cases with an update on classification and management[J]. Br J Dermatol, 2016,175(3):473⁃478. doi: 10.1111/bjd. 14543.
|
[18] |
Aguilera P. Inducing light tolerance with narrowband UV⁃B therapy in solar urticaria[J]. Actas Dermosifiliogr (Engl Ed), 2018,109(10):853. doi: 10.1016/j.ad.2018.06.009.
|
[19] |
Takahagi S, Tanaka A, Hide M. Sweat allergy[J]. Allergol Int, 2018,67(4):435⁃441. doi: 10.1016/j.alit.2018.07.002.
|
[20] |
Beissert S, Ständer H, Schwarz T. UVA rush hardening for the treatment of solar urticaria[J]. J Am Acad Dermatol, 2000,42(6):1030⁃1032. doi: 10.1016/s0190⁃9622(00)90299⁃8.
|
[21] |
Gaebelein⁃Wissing N, Ellenbogen E, Lehmann P. Solar urticaria: clinic, diagnostic, course and therapy management in 27 patients[J]. J Dtsch Dermatol Ges, 2020,18(11):1261⁃1268. doi: 10. 1111/ddg.14309.
|
[22] |
Borzova E, Rutherford A, Konstantinou GN, et al. Narrowband ultraviolet B phototherapy is beneficial in antihistamine⁃resistant symptomatic dermographism: a pilot study[J]. J Am Acad Dermatol, 2008,59(5):752⁃757. doi: 10.1016/j.jaad.2008. 07.016.
|
[23] |
Siiskonen H, Smorodchenko A, Krause K, et al. Ultraviolet radiation and skin mast cells: effects, mechanisms and relevance for skin diseases[J]. Exp Dermatol, 2018,27(1):3⁃8. doi: 10. 1111/exd.13402.
|
[24] |
Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria[J]. Allergy, 2018,73(7):1393⁃1414. doi: 10.1111/all.13397.
|
[25] |
宋晓婷, 刘擘, 陈玉迪, 等. 奥马珠单抗治疗27例人工荨麻疹回顾分析[J]. 中华皮肤科杂志, 2021,54(12):1092⁃1096. doi: 10.35541/cjd.20210473.
|
[26] |
Boyce JA. Successful treatment of cold⁃induced urticaria/anaphylaxis with anti⁃IgE[J]. J Allergy Clin Immunol, 2006,117(6):1415⁃1418. doi: 10.1016/j.jaci.2006.04.003.
|
[27] |
Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence[J]. J Allergy Clin Immunol, 2018,141(2):638⁃649. doi: 10.1016/j.jaci.2017.06.032.
|
[28] |
Pressler A, Grosber M, Halle M, et al. Failure of omalizumab and successful control with ketotifen in a patient with vibratory angio⁃oedema[J]. Clin Exp Dermatol, 2013,38(2):151⁃153. doi: 10. 1111/j.1365⁃2230.2012.04430.x.
|
[29] |
Can PK, Salman A, Hoşgören⁃Tekin S, et al. Effectiveness of omalizumab in patients with chronic inducible urticaria: real⁃life experience from two UCARE centres[J]. J Eur Acad Dermatol Venereol, 2021,35(10):e679⁃e682. doi: 10.1111/jdv.17385.
|
[30] |
Fialek M, Dezoteux F, Le Moing A, et al. Omalizumab in chronic inducible urticaria: a retrospective, real⁃life study[J]. Ann Dermatol Venereol, 2021:S0151⁃9638(21)00063⁃6. doi: 10. 1016/j.annder.2021.04.010.
|
[31] |
Bodar EJ, Simon A, de Visser M, et al. Complete remission of severe idiopathic cold urticaria on interleukin⁃1 receptor antagonist (anakinra)[J]. Neth J Med, 2009,67(9):302⁃305.
|
[32] |
Gualdi G, Monari P, Rossi MT, et al. Successful treatment of systemic cold contact urticaria with etanercept in a patient with psoriasis[J]. Br J Dermatol, 2012,166(6):1373⁃1374. doi: 10. 1111/j.1365⁃2133.2011.10797.x.
|
[33] |
Magerl M, Philipp S, Manasterski M, et al. Successful treatment of delayed pressure urticaria with anti⁃TNF⁃alpha[J]. J Allergy Clin Immunol, 2007,119(3):752⁃754. doi: 10.1016/j.jaci.2006. 12.658.
|
[34] |
Ferrucci S, Benzecry V, Berti E, et al. Rapid disappearance of both severe atopic dermatitis and cold urticaria following dupilumab treatment[J]. Clin Exp Dermatol, 2020,45(3):345⁃346. doi: 10.1111/ced.14081.
|
[35] |
Maurer M, Altrichter S, Metz M, et al. Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria[J]. J Eur Acad Dermatol Venereol, 2018,32(3):e112⁃e113. doi: 10.1111/jdv.14594.
|
[36] |
Bergmann KC, Altrichter S, Maurer M. Benefit of benralizumab treatment in a patient with chronic symptomatic dermographism[J]. J Eur Acad Dermatol Venereol, 2019,33(11):e413⁃e415. doi: 10.1111/jdv.15720.
|
[37] |
Dickson MC, Walker A, Grattan C, et al. Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: results of a phase 1a/b randomised double⁃blind placebo⁃controlled study[J]. Br J Clin Pharmacol, 2021 [2021⁃09⁃01]. https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp. 14923. doi: 10.1111/bcp.14923.
|